-0.07 (-0.951%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Weak
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Kezar Life Sciences Inc
Telephone
1.650.822.5600
Address
Suite 300, 4000 Shoreline Court, South San Francisco, CA 94080
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 3.53 - 7.55
Trade Value (12mth)
US$127,379.00
1 week
0%
1 month
0.14%
YTD
15.9%
1 year
81.8%
All time high
363.27
EPS 3 yr Growth
-24.40%
EBITDA Margin
0.00%
Operating Cashflow
-$52m
Free Cash Flow Return
-53.30%
ROIC
-57.60%
Interest Coverage
0.00
Quick Ratio
11.50
Shares Outstanding (Fully Diluted)
7m
HALO Sector
Healthcare
Next Company Report Date
23-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 11 May 26 | |
| 11 May 26 | |
| 11 May 26 | |
| 11 May 26 | |
| 11 May 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -14.04 | -11.49 | -7.66 | | | | ||
EPS (Fully Diluted) | $ | | | | | -14.04 | -11.49 | -7.66 | | | | ||
Growth | % | | | | | -38.6 | 18.2 | 33.3 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
